Media & Events

In transitioning from CDMO and cGMP biologics manufacturing to a AI-powered biotechnology company, iBio has changed leadership and location as part of their mission to become a stalwart in developing antibodies for hard-to-drug targets

iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.

The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it looks to dive further into drug discovery.